Compositions and methods for detecting plectin-1 as a biomarker for cancer
US-2015374862-A1 · Dec 31, 2015 · US
US9442107B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9442107-B2 |
| Application number | US-201514691826-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 21, 2015 |
| Priority date | Apr 27, 2010 |
| Publication date | Sep 13, 2016 |
| Grant date | Sep 13, 2016 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Disclosed herein are antibody-nanoparticle conjugates that include two or more nanoparticles (such as gold, palladium, platinum, silver, copper, nickel, cobalt, iridium, or an alloy of two or more thereof) directly linked to an antibody or fragment thereof through a metal-thiol bond. Methods of making the antibody-nanoparticle conjugates disclosed herein include reacting an arylphosphine-nanoparticle composite with a reduced antibody to produce an antibody-nanoparticle conjugate. Also disclosed herein are methods for detecting a target molecule in a sample that include using an antibody-nanoparticle conjugate (such as the antibody-nanoparticle conjugates described herein) and kits for detecting target molecules utilizing the methods disclosed herein.
Opening claim text (preview).
We claim: 1. A method for detecting a target molecule in a sample, comprising: (a) contacting the sample with a first antibody that specifically binds to the target molecule; (b) contacting the sample after step (a) with a second antibody conjugated to one or more enzyme molecules, wherein the second antibody specifically binds to the first antibody thereby forming a complex; (c) contacting the complex formed in step (b) above with a third antibody-nanoparticle conjugate wherein the third antibody specifically binds to the second antibody and wherein said third antibody-nanoparticle conjugate comprises three or more metal nanoparticles directly linked to a single third antibody through three or more metal-thiol bonds, wherein the metal-thiol bonds are between thiol of cysteine residues of the antibody and the three or more metal nanoparticles without an intervening linker; (d) contacting the sample after step (c) with a substrate of the enzyme and a metal ion, such that a metal precipitate forms and colocalizes with the target molecule; and (e) detecting the metal precipitate, thereby detecting the target molecule. 2. The method of claim 1 , wherein the target molecule comprises a hapten-labeled nucleic acid probe that specifically binds to the target molecule and wherein the first antibody specifically binds the hapten-labeled nucleic acid probe. 3. The method of claim 1 , wherein the nanoparticles comprise gold, palladium, platinum, silver, copper, nickel, cobalt, iridium, or an alloy of two or more thereof. 4. The method of claim 1 , wherein the metal ion comprises silver ion, gold ion, copper ion, nickel ion, platinum ion, palladium ion, cobalt ion, or iridium ion. 5. The method of claim 1 , further comprising a gold toning step comprising contacting the sample after step (d) with a gold halide salt. 6. The method of claim 5 , wherein the method further comprises amplifying the signal after the gold toning step. 7. The method of claim 6 , wherein the amplifying includes contacting with a silver salt selected from the group consisting of silver nitrate, silver oxide, silver acetate, and silver perchlorate. 8. The method according to claim 1 , further comprising contacting the sample with a reducing agent. 9. The method of claim 8 , wherein the reducing agent comprises sodium thiosulfate. 10. The method according to claim 1 , wherein the metal nanoparticles are about 5 nm or less in diameter. 11. The method according to claim 1 , wherein the single third antibody is directly linked to three to seven nanoparticles through said metal thiol bond without an intervening linker. 12. The method according to claim 1 , wherein the second antibody comprises a goat anti-rabbit immunoglobulin G antibody. 13. The method according to claim 1 , wherein the enzyme comprises an alkaline phosphatase, an acid phosphatase, a β-galactosidase, a β-glucosidase, a β-lactamase, or an esterase. 14. The method of claim 13 , wherein the enzyme is alkaline phosphatase and the substrate of the enzyme comprises 5-bromo-4-chloro-3-indolyl phosphate, ascorbic acid phosphate, or a hydroquinone phosphate derivative. 15. The method of claim 14 , wherein the second antibody is conjugated to three alkaline phosphate molecules. 16. The method according to claim 1 , wherein the target molecule comprises HER2, c-Myc, n-Myc, Abl, EGFR, IGF1R, c-Met, TOP2A, Bcl2, Bcl6, Rb1, p53, or MET.
Immunoglobulins · CPC title
Acyclic saturated phosphines · CPC title
Production of immunochemical test materials · CPC title
Complexes or chelates of phosphines with metallic compounds or metals · CPC title
condensed with carbocyclic rings or carbocyclic ring systems · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.